Market Closed -
Nasdaq
04:30:00 2024-05-03 pm EDT
|
5-day change
|
1st Jan Change
|
1.74
USD
|
+2.35%
|
|
+10.13%
|
+13.73%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
441
|
481.2
|
586.6
|
360.5
|
373.4
|
428.5
|
-
|
-
|
Enterprise Value (EV)
1 |
639.1
|
354.9
|
499.9
|
360.5
|
373.4
|
428.5
|
428.5
|
428.5
|
P/E ratio
|
3.58
x
|
-6.45
x
|
-6.57
x
|
-3.08
x
|
-1.94
x
|
-2.39
x
|
-2.53
x
|
-3.74
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
1.37
x
|
20.1
x
|
1,969
x
|
2,593
x
|
310
x
|
21.6
x
|
5.38
x
|
2.56
x
|
EV / Revenue
|
1.37
x
|
20.1
x
|
1,969
x
|
2,593
x
|
310
x
|
21.6
x
|
5.38
x
|
2.56
x
|
EV / EBITDA
|
2.54
x
|
-10.7
x
|
-6.76
x
|
-3.59
x
|
-2.18
x
|
-2.55
x
|
-3.4
x
|
-
|
EV / FCF
|
3,877,618
x
|
-3,363,760
x
|
-6,648,485
x
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
0%
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
3.77
x
|
3.09
x
|
5.17
x
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
106,272
|
140,704
|
148,896
|
188,726
|
244,025
|
246,237
|
-
|
-
|
Reference price
2 |
4.150
|
3.420
|
3.940
|
1.910
|
1.530
|
1.740
|
1.740
|
1.740
|
Announcement Date
|
3/12/20
|
3/10/21
|
2/28/22
|
3/2/23
|
3/11/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
322.1
|
24
|
0.298
|
0.139
|
1.204
|
19.83
|
79.6
|
167.4
|
EBITDA
1 |
173.7
|
-44.87
|
-86.8
|
-100.3
|
-171.2
|
-168
|
-126
|
-
|
EBIT
1 |
141.4
|
-47.8
|
-87.09
|
-100.8
|
-171.8
|
-197.4
|
-168.6
|
-176.3
|
Operating Margin
|
43.92%
|
-199.21%
|
-29,224.83%
|
-72,489.21%
|
-14,264.95%
|
-995.29%
|
-211.85%
|
-105.29%
|
Earnings before Tax (EBT)
1 |
124.1
|
-58.57
|
-87.76
|
-101.9
|
-175.6
|
-199.7
|
-179.2
|
-175.3
|
Net income
1 |
130.1
|
-58.57
|
-87.76
|
-101.9
|
-175.6
|
-199.7
|
-189
|
-142.9
|
Net margin
|
40.4%
|
-244.11%
|
-29,448.99%
|
-73,341.01%
|
-14,585.3%
|
-1,006.89%
|
-237.46%
|
-85.34%
|
EPS
2 |
1.160
|
-0.5300
|
-0.6000
|
-0.6200
|
-0.7900
|
-0.7273
|
-0.6890
|
-0.4650
|
Free Cash Flow
|
113.7
|
-143.1
|
-88.24
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
35.31%
|
-596.19%
|
-29,610.07%
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
65.47%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
87.4%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/12/20
|
3/10/21
|
2/28/22
|
3/2/23
|
3/11/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
-
|
0.014
|
0.037
|
0.035
|
0.039
|
0.028
|
0.024
|
0.317
|
0.162
|
0.702
|
1.13
|
3.25
|
6.35
|
12
|
EBITDA
1 |
-22.86
|
-25.22
|
-23.27
|
-
|
-
|
-
|
-
|
-
|
-
|
-46.59
|
-50.73
|
-46.04
|
-39.65
|
-
|
EBIT
1 |
-22.96
|
-25.33
|
-23.38
|
-24.01
|
-23.1
|
-30.28
|
-31.14
|
-44.24
|
-49.63
|
-46.74
|
-45.33
|
-50.1
|
-51.3
|
-50.7
|
Operating Margin
|
-
|
-180,928.57%
|
-63,189.19%
|
-68,591.43%
|
-59,217.95%
|
-108,135.71%
|
-129,758.33%
|
-13,955.84%
|
-30,636.42%
|
-6,657.69%
|
-4,011.77%
|
-1,541.54%
|
-807.87%
|
-422.5%
|
Earnings before Tax (EBT)
1 |
-23.12
|
-25.61
|
-23.48
|
-24.59
|
-23.39
|
-30.49
|
-31.93
|
-44.9
|
-50.52
|
-48.24
|
-48.4
|
-49.8
|
-51
|
-50.5
|
Net income
1 |
-23.12
|
-25.61
|
-23.48
|
-24.59
|
-23.39
|
-30.49
|
-31.93
|
-44.9
|
-50.52
|
-48.24
|
-48.4
|
-49.8
|
-51
|
-50.5
|
Net margin
|
-
|
-182,935.71%
|
-63,448.65%
|
-70,248.57%
|
-59,966.67%
|
-108,907.14%
|
-133,058.33%
|
-14,165.3%
|
-31,188.27%
|
-6,872.36%
|
-4,282.92%
|
-1,532.31%
|
-803.15%
|
-420.83%
|
EPS
2 |
-0.1600
|
-0.1700
|
-0.1600
|
-0.1600
|
-0.1300
|
-0.1600
|
-0.1700
|
-0.2200
|
-0.2100
|
-0.2000
|
-0.2000
|
-0.1856
|
-0.1810
|
-0.2033
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/3/21
|
2/28/22
|
5/5/22
|
8/2/22
|
11/9/22
|
3/2/23
|
5/2/23
|
8/3/23
|
11/8/23
|
3/11/24
|
5/2/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
198
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
126
|
86.7
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
1.14
x
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
114
|
-143
|
-88.2
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
287%
|
-139%
|
-65%
|
-88.4%
|
-167%
|
-1,181%
|
-
|
-
|
ROA (Net income/ Total Assets)
|
37.1%
|
-18.8%
|
-51.5%
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
350.9
|
310.8
|
170.3
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
1.100
|
1.110
|
0.7600
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
1.22
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
409.73%
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/12/20
|
3/10/21
|
2/28/22
|
3/2/23
|
3/11/24
|
-
|
-
|
-
|
Last Close Price
1.74
USD Average target price
5.25
USD Spread / Average Target +201.72% Consensus |
1st Jan change
|
Capi.
|
---|
| +13.73% | 428M | | -1.43% | 104B | | +8.96% | 105B | | +4.40% | 22.94B | | -12.15% | 22.34B | | -4.36% | 19.25B | | -39.98% | 17.08B | | -10.04% | 16.96B | | +6.79% | 14.16B | | +38.61% | 12.63B |
Bio Therapeutic Drugs
|